Silibinin Reduces the Impact of Obesity on Invasive Liver Cancer

Area of Science:

• Hepatology
• Oncology
• Metabolic Syndrome

Background:

• Obesity is linked to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
• Metabolic dysfunction and inflammation in obesity promote NASH and HCC development.
• Obesogenic factors trigger signaling pathways leading to lipogenesis, reactive oxygen species (ROS), and inflammation, contributing to liver cancer progression.

Purpose of the Study:

• To investigate the efficacy of silibinin in mitigating obesity-induced pro-tumorigenic effects relevant to liver cancer.
• To determine if silibinin can counteract the effects of sera from obese (OB), overweight (OW), and normal weight (NW) individuals on liver cancer cell characteristics.

Main Methods:

• An in vitro model using HepG2 liver cancer cells exposed to sera from OB, OW, and NW males.
• Assessment of cell growth, ROS production, lipogenesis, matrix metalloproteinase-9 (MMP-9) activity, and cell invasion.
• Analysis of protein expression, including fatty acid synthase (FASN), IL-6, IL-1B, and phosphorylated extracellular signal-regulated kinase (Erk).

Main Results:

• Silibinin significantly suppressed obesity-induced increases in HepG2 cell growth, ROS production, lipogenesis, MMP-9 activity, and cell invasion.
• These suppressive effects were associated with reduced expression of FASN, IL-6, IL-1B, and phosphorylated Erk.
• Differential effects of OB, OW, and NW sera on liver cancer characteristics were observed, highlighting obesity's pro-tumorigenic impact.

Conclusions:

• Silibinin demonstrates potential in mitigating obesity-associated pro-tumorigenic properties relevant to liver cancer.
• The findings suggest silibinin may be a therapeutic agent to delay liver cancer progression in obese individuals.
• This study provides insights into the molecular mechanisms underlying obesity's link to liver cancer and silibinin's potential role in intervention.